#USA #financial results #BioLife Solutions #Bothell #Repligen

BioLife Solutions Reports Impressive Second Quarter 2026 Financial Performance

Introduction
In a recent announcement, BioLife Solutions, Inc. (Nasdaq: BLFS) showcased its financial results for the second quarter of 2026, indicating robust growth and a promising future as it prepares for a significant acquisition by Repligen.

Financial Highlights
For the quarter ending June 30, 2026, BioLife Solutions reported a total revenue of $28.5 million. This figure represents a striking 21% increase from $23.4 million recorded in the same period last year, and up 4% from the previous quarter. The growth trajectory reflects the surge in demand for their advanced cell processing tools and services, primarily used in cell and gene therapy applications.

Net income surged to $45.1 million, a remarkable turnaround from the $15.3 million loss reported in Q2 2025. This significant jump can be attributed largely to a non-cash income tax benefit of $42.4 million, stemming from the release of a valuation allowance. Adjusted EBITDA for the same period was reported at $7.4 million, accounting for 26% of total revenue, marking a year-over-year increase from $5.6 million in Q2 2025.

Acquisition by Repligen
In an exciting development for stakeholders, BioLife has entered a definitive agreement for Repligen to acquire the company at an estimated enterprise value of approximately $1.5 billion. Under this agreement, shareholders will receive approximately $11.25 in cash and 0.1442 shares of Repligen's common stock for each share of BioLife's common stock they own. The acquisition is anticipated to close in the fourth quarter of 2026, pending stockholder and regulatory approvals.

Market Position
BioLife’s products play a critical role in the cell and gene therapy sector, being used in around 250 ongoing clinical trials in the U.S., which represents an impressive market share of over 70%. Among these, more than 30 are Phase III trials, insinuating that BioLife’s offerings are pivotal in advancing late-stage therapies. The company’s biopreservation media solutions are currently embedded in 18 unique commercial CGT products, with expectations for further approvals and expansions in the upcoming year.

Operational Metrics
Despite facing challenges, BioLife has managed to maintain a strong gross margin of 64% for Q2 2026, slightly down from 65% in the same quarter last year. The operating income for the second quarter stood at $1.7 million, a significant recovery from an operating loss of $16.1 million in Q2 2025. Furthermore, the adjusted operating income was reported at $3.1 million, a substantial improvement from the previous year.

Conclusion
Overall, BioLife Solutions has demonstrated its operational resilience and growth potential in the biotech sector. With the proposed acquisition by Repligen poised to reshape its future, stakeholders remain optimistic about the company's trajectory. The forthcoming enhancements in technology and market reach are expected to further solidify BioLife’s position as a leader in cell processing solutions, vital for the development of novel therapies in the evolving medical landscape. More information about their innovative products and business plans can be found at BioLife Solutions.

As the acquisition process unfolds, all eyes will be on BioLife to see how they capitalize on this strategic shift towards a united front in bio-processing excellence.